Long-Term Survival of Patients With Cancer, Sepsis, and Vasopressor Requirements Based on Lactate Levels-Reference-Cited by-同舟云学术

Long-Term Survival of Patients With Cancer, Sepsis, and Vasopressor Requirements Based on Lactate Levels

Published:2024-04 Issue:4 Volume:6 Page:e1070
ISSN:2639-8028
Container-title:Critical Care Explorations
language:en
Short-container-title:

Author:

Cuenca John A.¹²,Nates Joseph L.¹,Laserna Andres³,Heatter Alba J.¹,Manjappachar Nirmala¹,Martin Peyton¹,Reyes Maria P.¹,Hernandez Mike⁴,Hall Jacob¹,Ramirez Claudia M.¹,de Villalobos Diego H.¹

Affiliation:

1. Department of Critical Care Medicine, Division of Anesthesiology, Critical Care, and Pain Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

2. Internal Medicine residency, Texas Institute of Graduate Medical Education and Research (TIGMER), University of Incarnate Word, San Antonio, TX.

3. Department of Anesthesia and Perioperative Medicine, University of Rochester Medical Center, Rochester, NY.

4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

Abstract

A prospective cohort study was conducted to evaluate the 1-year survival of cancer patients with sepsis and vasopressor requirements. Eligible patients were admitted a Comprehensive Cancer Center’s ICU and were compared based on their admission lactate levels. Of the 132 included patients, 87 (66%) had high lactate (HL; > 2.0 mmol/L), and 45 (34%) had normal lactate (NL; ≤ 2.0 mmol/L). The 1-year survival rates of the two groups were similar (HL 16% vs. NL 18%; p = 0.0921). After adjustment for ICU baseline characteristics, HL was not significantly associated with a 1-year survival (Hazards ratio, 1.39; 95% CI, 0.94–2.05). Critically ill cancer patients with sepsis and vasopressor requirements, regardless of the lactate level, had 1-year survival of less than 20%. Large multicenter cancer registries would enable to confirm our findings and better understand the long-term trajectories of sepsis in this vulnerable population.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference14 articles.

1. Two decades of ICU utilization and hospital outcomes in a comprehensive cancer center.;Wallace;Crit Care Med,2016

2. The third international consensus definitions for sepsis and septic shock (Sepsis-3).;Singer;JAMA,2016

3. The impact of the Sepsis-3 septic shock definition on previously defined septic shock patients.;Sterling;Crit Care Med,2017

4. Outcomes and predictors of 28-day mortality in patients with hematologic malignancies and septic shock defined by Sepsis-3 criteria.;Manjappachar;J Natl Compr Canc Netw,2022

5. Outcomes and predictors of 28-day mortality in patients with solid tumors and septic shock defined by third international consensus definitions for sepsis and septic shock criteria.;Cuenca;Chest,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Septic shock in the immunocompromised cancer patient: a narrative review;Critical Care;2024-08-30

2. Cancer and sepsis: future challenges for long-term outcome;Current Opinion in Critical Care;2024-05-31